OncoCyte Corp (OCX) Stock Rating Lowered by Zacks Investment Research
OncoCyte Corp (NYSE:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Several other equities analysts also recently weighed in on the stock. Benchmark Co. lifted their price target on shares of OncoCyte Corp from $7.50 to $8.00 and gave the company a “speculative buy” rating in a report on Tuesday, June 7th. Canaccord Genuity reaffirmed a “buy” rating on shares of OncoCyte Corp in a report on Wednesday, June 15th.
OncoCyte Corp (NYSE:OCX) opened at 3.98 on Thursday. OncoCyte Corp has a 12-month low of $2.45 and a 12-month high of $10.24. The company’s 50 day moving average is $3.97 and its 200 day moving average is $4.45. The company’s market cap is $101.22 million.
OncoCyte Corp (NYSE:OCX) last announced its earnings results on Thursday, August 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Analysts forecast that OncoCyte Corp will post $0.04 earnings per share for the current fiscal year.
About OncoCyte Corp
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.